Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor with IC 50 of 0.3 nM. BLU2864 exhibits anti-tumor activity. BLU2864 has potential to be used in cancer and polycystic kidney disease research [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 139.00 | |
5 mg | In stock | $ 347.00 | |
10 mg | In stock | $ 563.00 | |
25 mg | In stock | $ 890.00 | |
50 mg | In stock | $ 1,230.00 | |
100 mg | In stock | $ 1,670.00 | |
500 mg | In stock | $ 3,350.00 |
Description | BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor with IC 50 of 0.3 nM. BLU2864 exhibits anti-tumor activity. BLU2864 has potential to be used in cancer and polycystic kidney disease research [1] [2]. |
In vitro | BLU2864 (40 nM and 200 nM; 5 d) shows inhibition of forskolin -induced cystogenesis in vitro[1]. Cell Viability Assay [1] Cell Line: mIMCD3 cells Concentration: 40 nM and 200 nM Incubation Time: 5 days Result: Inhibited forskolin induced in vitro cystogenesis of mIMCD3 cells cultured in Matrigel by 72% and 100% at 40 and 200 nM concentrations, respectively, relative to control. |
In vivo | BLU2864 administered via oral gavage at doses of 45 mg/kg and 30 mg/kg once daily for 5 days showed significant inhibition of renal PKA activity and amelioration of polycystic kidney disease (PKD) in Pkd1 RC/RC mice, indicated by reduced kidney basal and total PKA activities, decreased kidney weights, volumes relative to body weights, and cyst indices. Kidney basal and total PKA activities were suppressed significantly in treated mice compared to controls, with a noted increase in urine output and improved PKD symptoms at a dosage of 30 mg/kg. Additionally, BLU2864 treatment at dosages of 30 mg/kg and 75 mg/kg once daily for 34 days effectively retarded FLC tumor growth in vivo in mice bearing FLC PDX tumors, achieving tumor growth inhibition rates of 48.5% and 45.3%, respectively. |
Molecular Weight | 452.43 |
Formula | C24H19F3N4O2 |
CAS No. | 2810747-89-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (110.51 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BLU2864 2810747-89-6 Others BLU-2864 BLU 2864 inhibitor inhibit